Tirzepatide Once Weekly for the Treatment of Obesity

• Published in: The New England journal of medicine Vol. 387; no. 3; pp. 205 - 216
• Main Authors: Jastreboff, Ania M., Aronne, Louis J., Ahmad, Nadia N., Wharton, Sean, Connery, Lisa, Alves, Breno, Kiyosue, Arihiro, Zhang, Shuyu, Liu, Bing, Bunck, Mathijs C., Stefanski, Adam
• Format: Journal Article
• Language: English
• Published: United States Massachusetts Medical Society 21.07.2022
• Subjects: Adult; Adverse events; Anti-Obesity Agents - administration & dosage; Anti-Obesity Agents - pharmacology; Anti-Obesity Agents - therapeutic use; Antidiabetics; Body weight; Cardiovascular disease; Chronic illnesses; Clinical Medicine; Clinical Medicine General; Clinical trials; Diabetes; Diabetes mellitus; Diet; Dose-Response Relationship, Drug; Double-Blind Method; Endocrinology; FDA approval; Gastric Inhibitory Polypeptide - administration & dosage; Gastric Inhibitory Polypeptide - therapeutic use; Gastroenterology; GIP protein; GLP-1 receptor agonists; Glucagon; Glucagon-like peptide 1; Glucagon-Like Peptides - administration & dosage; Glucagon-Like Peptides - agonists; Glucagon-Like Peptides - therapeutic use; Humans; Injections, Subcutaneous; Lifestyles; Morbidity; Nutrition; Obesity; Obesity - complications; Obesity - drug therapy; Overweight; Peptides; Placebos; Statistical analysis; Treatment Outcome; Weight control; Weight Loss - drug effects

In this randomized trial, adults with obesity treated with weekly tirzepatide, a glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, had major weight loss over 72 weeks.